{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-108171","form_type":"8-K","ticker":"LITS","cik":"0001262104","company_name":"Lite Strategy, Inc.","filed_at":"2024-09-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.417770+00:00","generated_at":"2026-05-31T03:29:45.619183+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MEI Pharma reports $38.3M cash; continues evaluating strategic alternatives","bullets":["Cash, cash equivalents, and short-term investments at June 30, 2024: $38.3 million, with no outstanding debt.","Board commenced evaluation of strategic alternatives on July 22, 2024; Oppenheimer & Co. retained as exclusive financial adviser.","Reduction-in-force commenced August 1, 2024, continuing in stages; clinical development of voruciclib discontinued.","Options include out-licensing programs and M&A; company will not disclose developments unless completed or required."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-108171","json":"https://secwatch.observer/filing/0000950170-24-108171.json","markdown":"https://secwatch.observer/filing/0000950170-24-108171.md","text":"https://secwatch.observer/filing/0000950170-24-108171.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1262104/000095017024108171/0000950170-24-108171-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1262104/000095017024108171/meip-20240919.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T03:29:45.619183+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}